Coronavirus (COVID-19) News
Filter News
Found 2,554 articles
-
Eurofins Launches BQ.1 and BQ.1.1 Droplet Digital PCR Assay (ddPCR) for SARS-CoV-2 Wastewater Testing
12/5/2022
Eurofins Environment Testing Northern California: Wastewater and Eurofins Pandemic Prevention Services launched a droplet digital PCR assay for the combined quantitative analysis of SARS-CoV-2 Variants of Concern BQ.1 and BQ.1.1 in wastewater.
-
Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test
12/4/2022
$5 million raise to accelerate global market development & product development
-
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
12/1/2022
Halberd Corporation's Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
-
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
12/1/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
-
New Health+™ Long COVID Report Translates Lived Experiences into Evidence-Based Recommendations
11/30/2022
The US Department of Health and Human Services and its Office of the Assistant Secretary of Health recently released a Health+ Long COVID Human-Centered Design Report produced by Coforma's Health+™ program.
-
Dompé: New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in COVID-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines
11/30/2022
Dompé farmaceutici announced new data revealing a novel function of the SARS-CoV-2 Spike protein interaction with the human Estrogen Receptor Alpha that may lead to the severe coagulopathy observed in patients with COVID-19 and a minority of subjects receiving the SARS-CoV-2 vaccine.
-
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
11/30/2022
Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.
-
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
11/29/2022
Novavax, Inc. announced that the World Health Organization has issued an updated Emergency Use Listing for Nuvaxovid™ COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
-
In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma. -
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
11/24/2022
Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Sense and R-Biopharm Nederland B.V. Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in the Netherlands, Belgium, and Luxembourg
11/22/2022
Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with R-Biopharm Nederland B.V. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform.
-
Pfizer and BioNTech reported positive data Friday from their Omicron BA.4/BA.5-adapted bivalent booster. This followed a similar announcement by Moderna Monday. -
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
11/17/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology.
-
Pictor and Rako Science bring improved access to COVID-19 antibody testing for New Zealand with technology from Tasso
11/16/2022
Pictor, a global leader in immunodiagnostics, announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay antibody test will soon be available in New Zealand.
-
Curapath Announces Collaboration with Afrigen Biologics to Advance Development of African-owned mRNA SARS-CoV-2 Vaccine
11/16/2022
Curapath, a leader in the design, development, and custom manufacturing of polyamino-acid- and lipid-based nanoparticle delivery systems for therapeutics and vaccines, announced a collaboration with Afrigen Biologics to advance the development of the first African-owned mRNA SARS-Cov-2 vaccine.
-
World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.
11/14/2022
Late in 2021, Aerogen® and CanSinoBIO announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology.
-
The FDA's Pulmonary-Allergy Drugs Advisory Committee voted against the potential Emergency Use Authorization of the company’s COVID-19 therapeutic candidate, sabizabulin. -
AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States. It is also abandoning three early-stage programs. -
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia
11/10/2022
Sobi North America announced that the U.S. FDA issued an emergency use authorization for KINERET® for the treatment of COVID-19 in adult patients who are hospitalized with positive results of direct SARS-CoV-2 viral testing with pneumonia, requiring supplemental oxygen, and are at risk of progressing to severe respiratory failure, and are likely to have an increased blood level of a certain suPAR that may be a sign of increased risk of worsening of the disease.
-
BioGX Expands FDA EUA with pixl™ Portable qPCR System for its Direct-Sample COVID-19 Assay
11/10/2022
BioGX announced that the US FDA has updated their original Direct Sample Xfree™ COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR platforms, including BioGX’s pixl™ real-time PCR platform.